Carregant...
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2− Breast Cancer
Women with hormone receptor–positive, human epidermal growth factor receptor 2− negative breast cancer—the most common subtype—have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.
Guardat en:
| Publicat a: | P T |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MediMedia USA, Inc.
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4517534/ https://ncbi.nlm.nih.gov/pubmed/26236140 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|